Sollid, Ludvig M. http://orcid.org/0000-0001-8860-704X
Article History
Accepted: 8 January 2024
First Online: 9 February 2024
Competing interests
: During the past 3 years, the author has been a consultant for Bristol Myers Squibb, GSK, Mozart Therapeutics, Ono Pharmaceutical, Precigen ActoBio, Sanofi, SQZ Biotech, Takeda and Topas Therapeutics. He has also previously been a consultant for ImmusanT.